河北省药品监督管理局 2025年9月30日 （信息公开类型：主动公开） | | 河北省中药材GAP延伸检查结果信息表 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 企业名称 | 药品品种 | 中 药 材 | 中药材生产企 业名称 | 基地地址 | 基地 面积 | 经纬度坐标 | 检 查 结 | | | | 品 种 | | | | | 果 | | 神威药业 | 冠心宁注 | | 四川春盛药业 | 四川省成都市 彭州市敖平镇 | 650 亩 | 地块1兴平村，面积350亩E104°0′26″,N31°4′47； 地块2紫音泉村，面积300亩 E103°58′10″,N31°7′24″ | 符 | | 集团有限 | 射液、川 芎配方颗 | 川 芎 | 集团股份有限 | 四川省成都市 | 350 | | 合 要 | | 公司 | | | 公司 | | | | | | | 粒 | | | 彭州市葛仙山 镇官仓村 | 亩 | E103°59′18″,N31°6′59″ | 求 | | 神威药业 集团有限 | 冠心宁注 射液、川 | 川 ...

Core Viewpoint - Shenwei Pharmaceutical (02877) reported a decline in revenue and profit for the first half of 2025, indicating challenges in the market due to rising raw material costs and pricing pressures from centralized procurement [1] Financial Performance - Revenue for the first half of 2025 was 1.653 billion RMB, a decrease of 20.8% year-on-year [1] - Profit for the period was 615 million RMB, down 1.89% compared to the previous year [1] - Basic earnings per share were 0.81 RMB, with an interim dividend proposed at 0.11 RMB per share [1] Profitability Metrics - The group's gross profit margin decreased from 75.3% in the same period last year to 72.2% [1] - Despite the decline in sales and gross margin, net profit only slightly decreased by 1.9%, with the net profit margin increasing from 30.0% to 37.2% [1] Cost Management - The company managed to reduce selling and distribution costs and administrative expenses by approximately 20.7% and 12.9% respectively compared to the previous year [1] - Increased investment income contributed positively to the overall financial performance [1] Product Segment Performance - Oral formulations accounted for 65.8% of total sales in the first half of 2025, while injectable products made up 34.2% [1] - Total sales of injectable products decreased by 27.4% year-on-year, with significant declines in sales for specific products such as Qingkailing and Shenmai injections, which fell by 50.1% and 21.0% respectively [1]

Core Viewpoint - Shenwei Pharmaceutical (02877) reported a decline in revenue and profit for the first half of 2025, with total revenue at 1.653 billion RMB, down 20.8% year-on-year, and net profit at 615 million RMB, down 1.89% year-on-year [1] Financial Performance - The company's gross profit margin decreased from 75.3% in the same period last year to 72.2%, primarily due to rising raw material costs and the impact of centralized procurement on drug prices [1] - Operating profit for the first six months of 2025 also decreased compared to the same period last year, but net profit only slightly decreased by 1.9% due to increased investment income and cost control measures [1] - Sales and distribution costs and administrative expenses were reduced by approximately 20.7% and 12.9% respectively compared to the same period last year, resulting in a net profit margin increase from 30.0% to 37.2% [1] Product Sales Breakdown - Oral products accounted for 65.8% of total sales in the first half of 2025, while injectable products made up 34.2% [1] - Total sales of injectable products decreased by 27.4% year-on-year, with significant declines in sales for specific products such as Qingkailing injection and Shenmai injection, which fell by 50.1% and 21.0% respectively [2] - Other injectable products, including Shuxue Ning injection, Guanzhong Ning injection, and Danshen injection, also experienced sales declines of 6.3%, 9.6%, and 24.6% respectively [2]